X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2228) 2228
vidarabine - analogs & derivatives (1901) 1901
vidarabine - administration & dosage (1635) 1635
male (1598) 1598
female (1523) 1523
middle aged (1338) 1338
adult (1159) 1159
hematology (1129) 1129
aged (986) 986
index medicus (935) 935
oncology (899) 899
antineoplastic combined chemotherapy protocols - therapeutic use (838) 838
fludarabine (720) 720
treatment outcome (632) 632
vidarabine - therapeutic use (589) 589
cyclophosphamide - administration & dosage (581) 581
leukemia, lymphocytic, chronic, b-cell - drug therapy (549) 549
transplantation (511) 511
transplantation conditioning - methods (420) 420
adolescent (413) 413
vidarabine - adverse effects (412) 412
therapy (402) 402
rituximab (398) 398
immunology (365) 365
disease-free survival (339) 339
antineoplastic combined chemotherapy protocols - adverse effects (327) 327
transplantation, homologous (320) 320
antineoplastic combined chemotherapy protocols - administration & dosage (314) 314
cyclophosphamide (314) 314
remission induction (311) 311
bone-marrow-transplantation (301) 301
retrospective studies (280) 280
chemotherapy (278) 278
animals (273) 273
cytarabine - administration & dosage (267) 267
recurrence (266) 266
survival rate (262) 262
busulfan - administration & dosage (253) 253
cancer (252) 252
survival analysis (248) 248
aged, 80 and over (246) 246
child (242) 242
leukemia (238) 238
care and treatment (228) 228
follow-up studies (226) 226
stem-cell transplantation (226) 226
hematopoietic stem cell transplantation (225) 225
stem cells (225) 225
antineoplastic agents - administration & dosage (222) 222
chronic lymphocytic-leukemia (221) 221
antibodies, monoclonal - administration & dosage (218) 218
antineoplastic agents - therapeutic use (217) 217
drug administration schedule (216) 216
hematopoietic stem cell transplantation - methods (216) 216
young adult (213) 213
prognosis (208) 208
hematopoietic stem cells (206) 206
versus-host-disease (205) 205
chronic lymphocytic leukemia (198) 198
graft vs host disease - prevention & control (192) 192
health aspects (190) 190
risk factors (188) 188
research (185) 185
combined modality therapy (181) 181
dosage and administration (179) 179
transplantation conditioning (175) 175
acute myeloid-leukemia (168) 168
hematology, oncology and palliative medicine (166) 166
vidarabine - pharmacology (164) 164
alemtuzumab (161) 161
child, preschool (161) 161
time factors (159) 159
leukemia, lymphocytic, chronic, b-cell - pathology (156) 156
leukemia, myeloid, acute - drug therapy (155) 155
melphalan - administration & dosage (154) 154
hematopoietic stem cell transplantation - adverse effects (153) 153
mice (153) 153
antineoplastic agents (152) 152
antibodies, monoclonal, murine-derived (150) 150
survival (145) 145
antimitotic agents (144) 144
antibodies, monoclonal, murine-derived - administration & dosage (143) 143
mitoxantrone - administration & dosage (140) 140
acute myelogenous leukemia (139) 139
immunosuppressive agents - administration & dosage (139) 139
prospective studies (139) 139
leukemia, lymphocytic, chronic, b-cell - mortality (138) 138
regimen (133) 133
dose-response relationship, drug (132) 132
drug therapy, combination (129) 129
drug therapy (124) 124
hematologic neoplasms - therapy (124) 124
antilymphocyte serum - administration & dosage (122) 122
lymphoma (120) 120
bone-marrow transplantation (119) 119
busulfan (119) 119
medicine & public health (119) 119
non-hodgkins-lymphoma (119) 119
trial (118) 118
graft survival (117) 117
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2256) 2256
Japanese (42) 42
Chinese (35) 35
French (29) 29
German (17) 17
Spanish (17) 17
Russian (9) 9
Hungarian (7) 7
Polish (3) 3
Czech (2) 2
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IDARUBICIN | THERAPY | DOSE ARA-C | PEDIATRIC-PATIENTS | SENSITIVITY | RISK | CHILDHOOD LEUKEMIA | EXPERIENCE | ACCELERATED APPROVAL | ONCOLOGY GROUP | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Chemotherapy | Cytogenetics | Cancer therapies | Data bases | Cancer | Ovarian cancer
Journal Article
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 234 - 242
Journal Article
Leukemia, ISSN 0887-6924, 03/2007, Volume 21, Issue 3, pp. 524 - 528
Single-agent bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory... 
MULTIPLE-MYELOMA | SURVIVAL | cytarabine | APOPTOSIS | KAPPA-B ACTIVATION | combination treatment | CYCLOPHOSPHAMIDE | PHASE-II | TRIAL | IN-VITRO | ONCOLOGY | mantle cell lymphoma | NON-HODGKINS-LYMPHOMA | bortezomib | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Hodgkin's lymphoma | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - pharmacology | Mitoxantrone - administration & dosage | Apoptosis - drug effects | Cytarabine - therapeutic use | Humans | Middle Aged | Pyrazines - administration & dosage | Lymphoma, Mantle-Cell - pathology | Salvage Therapy | Drug Resistance, Neoplasm | Male | Cell Line, Tumor - drug effects | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Yttrium Radioisotopes - administration & dosage | Protease Inhibitors - pharmacology | Proteasome Endopeptidase Complex - drug effects | Protease Inhibitors - administration & dosage | Vincristine - administration & dosage | Female | Boronic Acids - administration & dosage | Protease Inhibitors - therapeutic use | Yttrium Radioisotopes - therapeutic use | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Bortezomib | Drug Administration Schedule | Lymphoma, Mantle-Cell - radiotherapy | Radioimmunotherapy | Lymphoma, Mantle-Cell - drug therapy | Combined Modality Therapy | Vidarabine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Drug Synergism | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Vidarabine - administration & dosage | Pyrazines - pharmacology | Boronic Acids - pharmacology | Cytarabine | Dosage and administration | Non-Hodgkin's lymphomas | Diagnosis | Research | Drug therapy
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report... 
Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Hodgkin's lymphoma | dexamethasone | refractory disease | THERAPY | thalidomide | RECURRENT | transplantation | DISEASE | cyclophosphamide | VINBLASTINE | PATIENT | HEMATOLOGY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1164 - 1174
Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal... 
Internal Medicine | CYTOKINE-RELEASE | MEDICINE, GENERAL & INTERNAL | PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | PROGRESSION-FREE SURVIVAL | INITIAL THERAPY | LYMPHOMA | STEM-CELL TRANSPLANTATION | EXPRESSION | III TRIAL | DELETION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Incidence | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Severity of Illness Index | Antibodies, Monoclonal, Murine-Derived | Drug Administration Schedule | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Disease Progression | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Patient outcomes | Dosage and administration | Research | Drug therapy | Studies | Clinical trials | Mutation | Medical statistics | Epidemiology | Annual meetings | Teaching hospitals
Journal Article
Blood, ISSN 0006-4971, 12/2003, Volume 102, Issue 13, pp. 4277 - 4283
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 35, pp. 4167 - 4175
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 2016, Volume 11, Issue 9, pp. 1681 - 1691
The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not... 
Paraproteins | Multiple myeloma M-proteins | Myeloma Proteins | Humans | Multiple myeloma | B-Lymphocytes | Kidney Failure | Lymphoma | Kidney | Chronic | Glomerular disease | Paraproteinemias | Plasma Cells | Proteinuria | SINGLE-AGENT CARFILZOMIB | MANTLE-CELL LYMPHOMA | REFRACTORY MULTIPLE-MYELOMA | LENALIDOMIDE PLUS DEXAMETHASONE | UNDETERMINED SIGNIFICANCE | UROLOGY & NEPHROLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | TERM-FOLLOW-UP | HIGH-DOSE CHEMOTHERAPY | CHAIN DEPOSITION DISEASE | MINIMAL RESIDUAL DISEASE | Cyclophosphamide - administration & dosage | Pentostatin - administration & dosage | Dexamethasone - administration & dosage | Paraproteinemias - drug therapy | Paraproteinemias - diagnosis | Immunosuppressive Agents - therapeutic use | Kidney Diseases - drug therapy | Paraproteinemias - complications | Vidarabine - analogs & derivatives | Immunoglobulins - metabolism | Rituximab - administration & dosage | Thalidomide - analogs & derivatives | Bendamustine Hydrochloride - administration & dosage | Melphalan - administration & dosage | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Kidney Diseases - etiology | Thalidomide - therapeutic use | Kidney Diseases - metabolism | multiple myeloma | proteinuria | multiple myeloma M-proteins | glomerular disease | kidney | Mini-Reviews
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 6, pp. 641 - 650
Abstract We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease... 
Hematology, Oncology and Palliative Medicine | Bone marrow transplantation | Cyclophosphamide | Histocompatibility antigens | Conditioning regimens | Lymphoma | Leukemia | TOTAL-BODY IRRADIATION | leukemia | IMMUNE RECONSTITUTION | lymphoma | UNRELATED DONORS | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | bone marrow transplantation | TRANSPLANTATION | histocompatibility antigens | CORD BLOOD TRANSPLANTATION | DRUG-INDUCED TOLERANCE | IDENTICAL SIBLINGS | cyclophosphamide | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MYCOPHENOLATE-MOFETIL | conditioning regimens | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Recombinant Proteins | Bone Marrow Transplantation - methods | Cyclophosphamide - therapeutic use | Filgrastim | Transplantation, Homologous | Bone Marrow Transplantation - immunology | Adult | Female | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Drug Administration Schedule | Graft Survival | Postoperative Complications - epidemiology | Vidarabine - analogs & derivatives | Granulocyte Colony-Stimulating Factor - therapeutic use | Postoperative Care - methods | Blood Component Transfusion | Hematologic Neoplasms - surgery | Disease-Free Survival | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Hemoglobinuria, Paroxysmal - surgery | Cyclophosphamide - pharmacology | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Histocompatibility | Antimitotic agents | Evaluation | Mortality | Bone marrow | Dosage and administration | Transplantation | Antineoplastic agents | T cells | Cancer | Index Medicus
Journal Article